Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening.

Walter JE, Heuvelmans MA, Oudkerk M.

Transl Lung Cancer Res. 2017 Feb;6(1):42-51. doi: 10.21037/tlcr.2016.11.05. Review.


Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.

Sullivan FM, Farmer E, Mair FS, Treweek S, Kendrick D, Jackson C, Robertson C, Briggs A, McCowan C, Bedford L, Young B, Vedhara K, Gallant S, Littleford R, Robertson J, Sewell H, Dorward A, Sarvesvaran J, Schembri S.

BMC Cancer. 2017 Mar 11;17(1):187. doi: 10.1186/s12885-017-3175-y.


Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.

Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF.

PLoS Med. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb.


Smokers with emphysema and small airway disease on computed tomography have lower bone density.

Pompe E, de Jong PA, van Rikxoort EM, Gallardo Estrella L, de Jong WU, Vliegenthart R, Oudkerk M, van der Aalst CM, van Ginneken B, Lammers JW, Mohamed Hoesein FA.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1207-16. doi: 10.2147/COPD.S103680. eCollection 2016.


Risk factors assessment and risk prediction models in lung cancer screening candidates.

Adamek M, Wachuła E, Szabłowska-Siwik S, Boratyn-Nowicka A, Czyżewski D.

Ann Transl Med. 2016 Apr;4(8):151. doi: 10.21037/atm.2016.04.03. Review.


The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients.

Quaife SL, Ruparel M, Beeken RJ, McEwen A, Isitt J, Nolan G, Sennett K, Baldwin DR, Duffy SW, Janes SM, Wardle J.

BMC Cancer. 2016 Apr 20;16:281. doi: 10.1186/s12885-016-2316-z.


Diagnosis of diffuse idiopathic skeletal hyperostosis with chest computed tomography: inter-observer agreement.

Oudkerk SF, de Jong PA, Attrach M, Luijkx T, Buckens CF, Mali WP, Oner FC, Resnick DL, Vliegenthart R, Verlaan JJ.

Eur Radiol. 2017 Jan;27(1):188-194. Epub 2016 Apr 20.


Recommendations on screening for lung cancer.

Canadian Task Force on Preventive Health Care., Lewin G, Morissette K, Dickinson J, Bell N, Bacchus M, Singh H, Tonelli M, Jaramillo Garcia A.

CMAJ. 2016 Apr 5;188(6):425-32. doi: 10.1503/cmaj.151421. Epub 2016 Mar 7. Review. No abstract available.


Inter-observer and inter-examination variability of manual vertebral bone attenuation measurements on computed tomography.

Pompe E, de Jong PA, de Jong WU, Takx RA, Eikendal AL, Willemink MJ, Oudkerk M, Budde RP, Lammers JW, Mohamed Hoesein FA.

Eur Radiol. 2016 Sep;26(9):3046-53. doi: 10.1007/s00330-015-4145-x. Epub 2016 Jan 22.


UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.

Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, Eisen T, Gosney J, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rassl DM, Rintoul RC, Screaton NJ, Wald NJ, Weller D, Williamson PR, Yadegarfar G, Hansell DM.

Thorax. 2016 Feb;71(2):161-70. doi: 10.1136/thoraxjnl-2015-207140. Epub 2015 Dec 8.


Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Optican RJ, Chiles C.

Transl Lung Cancer Res. 2015 Aug;4(4):353-64. doi: 10.3978/j.issn.2218-6751.2015.07.14. Review.


Lung cancer screening: Computed tomography or chest radiographs?

van Beek EJ, Mirsadraee S, Murchison JT.

World J Radiol. 2015 Aug 28;7(8):189-93. doi: 10.4329/wjr.v7.i8.189.


Attitudes towards Lung Cancer Screening in an Australian High-Risk Population.

Flynn AE, Peters MJ, Morgan LC.

Lung Cancer Int. 2013;2013:789057. doi: 10.1155/2013/789057. Epub 2013 Jul 15.


Lung cancer screening: identifying the high risk cohort.

Marcus MW, Raji OY, Field JK.

J Thorac Dis. 2015 Apr;7(Suppl 2):S156-62. doi: 10.3978/j.issn.2072-1439.2015.04.19. Review.


Prognostic value of heart valve calcifications for cardiovascular events in a lung cancer screening population.

Willemink MJ, Takx RA, Išgum I, de Koning HJ, Oudkerk M, Mali WP, Budde RP, Leiner T, Vliegenthart R, de Jong PA.

Int J Cardiovasc Imaging. 2015 Aug;31(6):1243-9. doi: 10.1007/s10554-015-0664-4. Epub 2015 May 12.


The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.

Lee MC, Buitrago DH, Kadota K, Ujiie H, Woo K, Sima CS, Travis WD, Jones DR, Adusumilli PS.

Oncoimmunology. 2014 Dec 21;3(11):e967142. eCollection 2014 Nov.


ESR/ERS white paper on lung cancer screening.

Kauczor HU, Bonomo L, Gaga M, Nackaerts K, Peled N, Prokop M, Remy-Jardin M, von Stackelberg O, Sculier JP; European Society of Radiology (ESR).; European Respiratory Society (ERS)..

Eur Respir J. 2015 Jul;46(1):28-39. doi: 10.1183/09031936.00033015. Epub 2015 Apr 30.


ESR/ERS white paper on lung cancer screening.

Kauczor HU, Bonomo L, Gaga M, Nackaerts K, Peled N, Prokop M, Remy-Jardin M, von Stackelberg O, Sculier JP; European Society of Radiology (ESR).; European Respiratory Society (ERS)..

Eur Radiol. 2015 Sep;25(9):2519-31. doi: 10.1007/s00330-015-3697-0. Epub 2015 May 1.


Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Kadota K, Yeh YC, Villena-Vargas J, Cherkassky L, Drill EN, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Chest. 2015 Sep;148(3):711-21. doi: 10.1378/chest.14-3005.


Large scale validation of the M5L lung CAD on heterogeneous CT datasets.

Torres EL, Fiorina E, Pennazio F, Peroni C, Saletta M, Camarlinghi N, Fantacci ME, Cerello P.

Med Phys. 2015 Apr;42(4):1477-89. doi: 10.1118/1.4907970.

Supplemental Content

Support Center